Reduced frequency pembrolizumab immunotherapy: can the frequency of pembrolizumab treatment for non-small cell lung cancer be reduced without reducing its effectiveness?

To determine the optimal dose frequency of pembrolizumab amongst patients with NSCLC who have benefited from and completed 6 months of standard therapy. To determine the longest frequency of pembrolizumab treatment that has similar effectiveness in terms of the following when compared to standard 6 weekly pembrolizumab in NSCLC patients who have completed and benefitted from 6 months of standard treatment: • Overall survival (OS); • Progression free survival (PFS), or the length of time that a participant is alive and the cancer has not come back or grown significantly; • Overall response rate (ORR), or the proportion of participants for whom the cancer either disappears or shrinks significantly; • Duration of response (DoR), or, in the proportion of patients for whom the cancer either disappears or shrinks significantly, the length of time between the disappearance or shrinking significantly and the shrinking stopping or the cancer coming back or growing significantly; • Safety and tolerability, or the side effects that are related to pembrolizumab; • Quality of life (QoL); • Cost effectiveness.